Skip to main
CNMD

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 0%
Buy 17%
Hold 83%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp has demonstrated notable growth in its high-potential segments, particularly with the recent success of the BioBrace, which is expected to further bolster revenue following its full release in the third quarter of 2025. The dual-digit growth observed in the Foot & Ankle category, despite supply constraints, indicates a potential easing of these issues and reflects a resilient demand for the company's products. Management's cautious revenue guidance reinforces the company’s commitment to a sustainable top-line turnaround, further supporting a positive outlook for Conmed's financial performance.

Bears say

Conmed Corp has experienced a 27% decline in its stock year-to-date, indicating significant challenges in its turnaround efforts. The company faces ongoing capital weakness, particularly in international markets, which can be attributed to difficult year-over-year comparisons rather than an overall slowdown in hospital capital budgets. This situation has led to a revision of the price target, reflecting the company's struggles amidst a backdrop of intensified competitive pressures and operational challenges.

CONMED (CNMD) has been analyzed by 6 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 17% recommend Buy, 83% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Hold based on their latest research and market trends.

According to 6 analysts, CONMED (CNMD) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.